Werner Scheuer
Roche Pharma AG (Germany)(DE)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Glycosylation and Glycoproteins Research, Angiogenesis and VEGF in Cancer, HER2/EGFR in Cancer Research, Radiopharmaceutical Chemistry and Applications
Most-Cited Works
- → Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models(2009)622 cited
- → Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies(2011)462 cited
- → Interleukin‐16 stimulates the expression and production of pro‐inflammatory cytokines by human monocytes(2000)258 cited
- → Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy(2013)197 cited
- Cancer-related issues of CD147.(2010)
- → RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis(2016)131 cited
- → Multispectral Fluorescence Ultramicroscopy: Three-Dimensional Visualization and Automatic Quantification of Tumor Morphology, Drug Penetration, and Antiangiogenic Treatment Response(2014)105 cited
- → Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy(2005)95 cited
- → Bispecific digoxigenin-binding antibodies for targeted payload delivery(2011)70 cited
- → Quantification of human Alu sequences by real-time PCR – an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants(2002)69 cited